How concrete are vaccine efficacy claims by Pfizer, Moderna, Gamaleya
1 of 7
Three vaccine candidates have declared the interim results of their phase III trials so far. All of them have claimed more than 90 per cent efficacy by assessing the smaller data. Of all the three, Pfizer and BioNTech's vaccine candidate, BNT162b2, has shown the highest efficacy of 95 per cent.
Story: Mudit Kapoor
Design: Mohsin Shaikh